These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34019448)

  • 1. [The Current Significance of Measuring HDL-Cholesterol in Cardiovascular Risk Assessment].
    Wallimann-Annema W
    Praxis (Bern 1994); 2021; 110(7):383-390. PubMed ID: 34019448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
    Carr SS; Hooper AJ; Sullivan DR; Burnett JR
    Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    Ascaso JF; Fernández-Cruz A; González Santos P; Hernández Mijares A; Mangas Rojas A; Millán J; Felipe Pallardo L; Pedro-Botet J; Pérez-Jiménez F; Pía G; Pintó X; Plaza I; Rubiés-Prat J;
    Am J Cardiovasc Drugs; 2004; 4(5):299-314. PubMed ID: 15449972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    von Eckardstein A
    Praxis (Bern 1994); 2017 Aug; 106(17):941-948. PubMed ID: 28830319
    [No Abstract]   [Full Text] [Related]  

  • 5. From High-Density Lipoprotein Cholesterol to Measurements of Function: Prospects for the Development of Tests for High-Density Lipoprotein Functionality in Cardiovascular Disease.
    Sacks FM; Jensen MK
    Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):487-499. PubMed ID: 29371248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk.
    Allard-Ratick MP; Kindya BR; Khambhati J; Engels MC; Sandesara PB; Rosenson RS; Sperling LS
    Eur J Prev Cardiol; 2021 Apr; 28(2):166–173. PubMed ID: 33838035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting high-density lipoproteins: update on a promising therapy.
    Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
    Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDL Cholesterol Efflux Capacity: Cardiovascular Risk Factor and Potential Therapeutic Target.
    Bhatt A; Rohatgi A
    Curr Atheroscler Rep; 2016 Jan; 18(1):2. PubMed ID: 26710794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Not Available].
    Kronenberg F
    Praxis (Bern 1994); 2017 Aug; 106(17):949-954. PubMed ID: 28830318
    [No Abstract]   [Full Text] [Related]  

  • 13. Treating high density lipoprotein cholesterol (HDL-C): quantity versus quality.
    Pirillo A; Norata GD; Catapano AL
    Curr Pharm Des; 2013; 19(21):3841-57. PubMed ID: 23286430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.
    de Fost M; Langeveld M; Franssen R; Hutten BA; Groener JE; de Groot E; Mannens MM; Bikker H; Aerts JM; Kastelein JJ; Hollak CE
    Atherosclerosis; 2009 May; 204(1):267-72. PubMed ID: 18842264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
    Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
    Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should we take high-density lipoprotein cholesterol levels at face value?
    Leite JO; Fernandez ML
    Am J Cardiovasc Drugs; 2010; 10(1):1-3. PubMed ID: 20104929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study.
    van Capelleveen JC; Bochem AE; Boekholdt SM; Mora S; Hoogeveen RC; Ballantyne CM; Ridker PM; Sun W; Barter PJ; Tall AR; Zwinderman AH; Kastelein JJP; Wareham NJ; Khaw KT; Hovingh GK
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28775061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal therapy of low levels of high density lipoprotein-cholesterol.
    Kashyap ML; Tavintharan S; Kamanna VS
    Am J Cardiovasc Drugs; 2003; 3(1):53-65. PubMed ID: 14727946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-high-density lipoprotein cholesterol: current status as cardiovascular marker.
    Verbeek R; Hovingh GK; Boekholdt SM
    Curr Opin Lipidol; 2015 Dec; 26(6):502-10. PubMed ID: 26780004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HDL cholesterol: reappraisal of its clinical relevance.
    März W; Kleber ME; Scharnagl H; Speer T; Zewinger S; Ritsch A; Parhofer KG; von Eckardstein A; Landmesser U; Laufs U
    Clin Res Cardiol; 2017 Sep; 106(9):663-675. PubMed ID: 28342064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.